Cephalon pays CEO more than hefty rivals

Which drug exec gets paid 140 percent more than the median among his peers? Hint: His company makes the anti-narcolepsy med Provigil. And he made a cool $13.5 million last year (the AP says $16 million). That paycheck included a $1.2 million salary, $2.2 million in bonus, and $10.1 million in stock and options.

If you said Cephalon CEO Frank Baldino (photo), you're correct. Baldino beat out Big Pharma chiefs Jeff Kindler ($9.5 million, according to the WSJ) and Bristol-Myers Squibb's Jim Cornelius ($11.3 million). That's saying something, considering the fact that Cephalon's $1.8 billion in revenues is dwarfed by Pfizer's $48.6 billion and Bristol's $19 billion.

Actually, Baldino qualified for an even bigger bonus, the company said, but its compensation committee decided to shave a bit off the top because of Cephalon's recent $425 million settlement with the U.S. Attorney's office in Philadelphia. The company was under investigation for off-label marketing violations.

- read the item at the WSJ Health Blog
- check out the AP's figures here

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.